Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Serious adverse events (n/N)

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 1.72 [0.91, 3.28]
2 studies · 763 participants
Low

Serious adverse events (n/N)

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 0.95 [0.75, 1.21]
9 studies · 3332 participants
Moderate